Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.50 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795327 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ATDP1LMNA | |
| SCHEMBL2029216 | 0.84 | SMN1; SMN2 (0.51) | GABRA5GABRB2HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL5544014 | 0.82 | SMN1; SMN2 (0.57) | GABRA5GABRB2HSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL5544118 | 0.81 | MAPT (0.56) | SMN1; SMN2NPC1RAB9ATDP1MAPT | |
| SCHEMBL12883290 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ATDP1LMNA | |
| SCHEMBL8538449 | 0.81 | MAPT (0.54) | SMN1; SMN2NPC1RAB9ATDP1LMNA | |
| SCHEMBL12780860 | 0.80 | MAPT (0.58) | HSD17B10SMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL16770015 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ATDP1LMNA | |
| SCHEMBL12868364 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ATDP1LMNA | |
| SCHEMBL12158564 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ATDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| US-20250354196-A1 | BORANES ON SOLID SUPPORTS | ILLUMINA, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4634403-A1 | BORANES ON SOLID SUPPORTS | Illumina, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4563146-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4469457-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | The Broad Institute Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024130031-A1 | BORANES ON SOLID SUPPORTS | ILLUMINA, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023147015-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-1042905-A | The preparation method of 2 (1H) quinolinone compounds and medicinal compositions thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1990-06-13 | — | — | CN | disclosed |
| EP-0370381-A2 | 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4777163-A | BONE DISORDERS, RHEUMATIC DISEASES | BOEHRINGER MANNHEIM GMBH (DE) | 1988-10-11 | — | — | US | disclosed |
| EP-0258618-A2 | Diphosphonic acid derivatives, process for their preparation and medicines containing those compounds | Roche Diagnostics GmbH (DE) | 1988-03-09 | — | — | EP | disclosed |
| US-4683227-A | CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| US-4665066-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0211526-A2 | Cephalosporins, their preparation and formulations | ELI LILLY AND COMPANY (US) | 1987-02-25 | — | — | EP | disclosed |
| EP-0066993-B1 | QUINOLINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-01-30 | — | — | EP | disclosed |
| US-4435405-A | 2-(AMINOALKYLTHIO) SUBSTITUTED | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-03-06 | — | — | US | disclosed |
| EP-0066993-A1 | Quinoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | CSNK1A1, CSNK2A1, CSNK1A1L | GABRA5 2954/4885GABRB2 3384/4885HSD17B10 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.